Remove 2028 Remove Pharmaceuticals Remove Therapies
article thumbnail

WuXi Biologics, VISEN Partner to Make Lonapegsomatropin in Chengdu

The Pharma Data

This new chapter in the strategic partnership between WuXi Biologics and VISEN Pharmaceuticals underscores a shared commitment to innovation, localization, and improved patient care. VISEN Pharmaceuticals expects to obtain regulatory approval for lonapegsomatropin in China by 2025.

article thumbnail

The Competitive Edge of Biosimilars

DrugBank

This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles. billion by 2028. One key challenge is the development of biosimilars for complex biologics, such as monoclonal antibodies used in cancer treatment and gene therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2021 Biotech IPOs Get Off to a Roaring Start

The Pharma Data

TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies.

article thumbnail

Article EMA Thank You British regulators tease new device regulations in informative live session

Agency IQ

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. An example: For GSPR 12 on devices that incorporate medicinal products, rather than citing the European pharmaceutical regulations (Directive 2001/83/EC), the U.K. government continued to recognize CE-marked products for a limited time.

article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.  Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15 billion by 2030.

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Last year, Jakafi brought in nearly $2.8 billion in sales.

Licensing 124
article thumbnail

Bayer, Broad Institute Extend Cardiovascular Drug Research Pact

The Pharma Data

The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.